Repligen Corp (RGEN)
167.80
-3.48
(-2.03%)
USD |
NASDAQ |
Apr 24, 16:00
167.51
-0.29
(-0.17%)
After-Hours: 16:57
Repligen Research and Development Expense (Quarterly): 10.28M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 10.28M |
| September 30, 2023 | 10.58M |
| June 30, 2023 | 9.706M |
| March 31, 2023 | 12.15M |
| December 31, 2022 | 11.11M |
| September 30, 2022 | 10.23M |
| June 30, 2022 | 10.44M |
| March 31, 2022 | 12.16M |
| December 31, 2021 | 9.119M |
| September 30, 2021 | 9.154M |
| June 30, 2021 | 8.389M |
| March 31, 2021 | 7.612M |
| December 31, 2020 | 6.722M |
| September 30, 2020 | 4.422M |
| June 30, 2020 | 4.336M |
| March 31, 2020 | 4.702M |
| December 31, 2019 | 5.172M |
| September 30, 2019 | 5.427M |
| June 30, 2019 | 5.231M |
| March 31, 2019 | 3.62M |
| December 31, 2018 | 3.152M |
| September 30, 2018 | 3.601M |
| June 30, 2018 | 5.78M |
| March 31, 2018 | 3.288M |
| December 31, 2017 | 3.069M |
| Date | Value |
|---|---|
| September 30, 2017 | 2.001M |
| June 30, 2017 | 1.86M |
| March 31, 2017 | 1.742M |
| December 31, 2016 | 2.039M |
| September 30, 2016 | 1.886M |
| June 30, 2016 | 1.89M |
| March 31, 2016 | 1.539M |
| December 31, 2015 | 1.431M |
| September 30, 2015 | 1.49M |
| June 30, 2015 | 1.252M |
| March 31, 2015 | 1.568M |
| December 31, 2014 | 1.328M |
| September 30, 2014 | 1.65M |
| June 30, 2014 | 1.430M |
| March 31, 2014 | 1.201M |
| December 31, 2013 | 1.422M |
| September 30, 2013 | 1.430M |
| June 30, 2013 | 2.306M |
| March 31, 2013 | 2.183M |
| December 31, 2012 | 2.343M |
| September 30, 2012 | 2.433M |
| June 30, 2012 | 2.906M |
| March 31, 2012 | 2.808M |
| September 30, 2011 | 3.075M |
| June 30, 2011 | 3.518M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
4.336M
Minimum
Jun 2020
12.16M
Maximum
Mar 2022
8.260M
Average
9.119M
Median
Dec 2021
Research and Development Expense (Quarterly) Benchmarks
| Perspective Therapeutics Inc | 6.08M |
| Retractable Technologies Inc | 0.1617M |
| Xtant Medical Holdings Inc | 0.492M |
| Asensus Surgical Inc | 8.614M |
| Catheter Precision Inc | -0.011M |